Pricing Log in Create free account
Saturday 17 October 2026 Export ENOV’s income statement to Excel — free account

Enovis Corporation

ENOV Healthcare Medical Devices

Enovis Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 6.66% from fiscal 2024. In the quarter to June 2026, revenue grew 3.23%, EPS grew 96.9%, free cash flow grew 815.8% and total debt fell 7.82%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

19.59 0.24 +1.24%
Market cap
$1.1B
P/E
0.0×
Fwd P/E
195×
Dividend yield
—
F-score
4/9
Altman Z
−0.34
Beneish M
−4.29
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.76
Total sells 0.05
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy 1 — — 1 4 — — 4 — — 3 —
Sell — 1 — — — — — — — — — —
Insider Ownership 2.36%

Capital & Financial Ratios $m

Market Cap 1,120.00
Revenue 2,296.60
Net Income (1,100.85)
Free Cash Flow 63.66
Net Debt 1,271.95
Current Ratio 1.98 (at or above 1.5: strong)
Debt/Equity 0.87
P/E ratio 0.00
Fwd P/E 195.00 (above 35: high)
P/S ratio 0.49
P/B ratio 0.76
Past 5Y EPS Growth —
This Y EPS Growth 9.91%
Next Y EPS Growth (2.31%) (below 0%: weak)
Next Y revenue growth 4.05%
Next 5Y EPS Growth 6.00%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.0×, against a ten-year median of 1.6×; over the ten years it ranged from 0.8× in 2016 to 13.0× in 2021.
P/S against its own 10 years 2.58%
10-year low 10-year high
P/B against its own 10 years 43.24%
10-year low 10-year high
EV/Sales against its own 10 years 8.51%
10-year low 10-year high
EV/FCF against its own 10 years 66.63%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2026 Powerpack
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 36 48 36 13
Receivables 291 407 443 442
Inventory 469 547 584 602
Other 71 108 101 110
897 1,146 1,207 1,215
2023 2024 2025 Q'26
Payables 132 179 188 194
ST’ Debt — 20 35 37
Other — — — —
370 529 598 612

Compound Annual Growth %

10y 5y 3y
Sales (4.15%) 14.94% 12.88%
Cash Flow (3.30%) (6.37%) 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (7.51%) (16.10%) (24.38%)

Revenue $m

Mar Jun Sep Dec Year
’26 589 583 — — —
’25 559 565 549 576 2,248
’24 516 525 505 561 2,108
’23 406 429 418 455 1,707
’22 375 395 384 409 1,563
’21 879 356 360 (169) 1,426
’20 816 620 806 (1,122) 1,121
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 24 75 — — —
’25 (2) 48 83 89 217
’24 (36) 8 54 88 114
’23 7 28 31 68 135
’22 (14) (25) 19 (36) (56)
’21 84 78 97 96 356
’20 56 37 80 129 302
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (29) 31 — — —
’25 (45) 3 29 32 20
’24 (73) (32) 2 35 (67)
’23 (23) (9) 47 30 45
’22 (36) (49) (1) (73) (159)
’21 60 61 68 70 259
’20 27 21 49 100 197
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.15) (0.02) — — —
’25 (0.98) (0.64) (9.99) (9.10) (20.75)
’24 (1.32) (0.34) (0.58) (12.05) (14.93)
’23 (0.43) (0.18) (0.05) 0.05 (0.61)
’22 0.33 1.41 (1.23) (0.71) (0.25)
’21 0.39 0.54 0.48 (0.03) 1.38
’20 0.09 (0.18) 0.30 0.72 0.93
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 31.36 57.33 32.62 34.44 21.05 62.98 43.88 43.04 38.27 25.47

Analyst estimates 2026–2028

Powerpack
High 68.57 74.51 72.43 63.30 67.64 94.10 81.94 66.71 65.03 49.38
People
People Employees 13,000 14,300 15,500 15,000 15,400 16,200 6,800 6,550 7,367 7,802
Revenue/emp, $m 0.25 0.14 0.14 0.22 0.07 0.09 0.23 0.26 0.29 0.29
Income, $m
Income, $m Revenue 3,186 1,937 2,193 3,327 1,121 1,426 1,563 1,707 2,108 2,248
Gross margin, % 31.15 34.67 33.26 42.11 53.86 54.53 55.62 58.04 56.02 59.84
EBT 207 49 92 50 (119) (122) (2) (67) (823) (1,159)
EBT margin, % 6.48 2.51 4.21 1.52 (10.62) (8.54) (0.13) (3.93) (39.05) (51.57)
Net income 145 170 154 (517) 46 76 (12) (33) (825) (1,184)
Depreciation 143 316 149 236 246 263 220 217 935 1,344
Per share, $
Per share, $ Revenue 77.76 47.17 54.70 73.56 24.58 27.89 28.91 31.33 38.13 39.39
Earnings 3.12 3.69 3.48 (11.67) 0.93 1.41 (0.25) (0.61) (14.93) (20.75)
Cash flow 6.03 5.33 5.65 2.89 6.62 6.96 (1.03) 2.48 2.05 3.81
Capex (1.37) (1.16) (0.87) (2.60) (2.31) (1.90) (1.90) (1.65) (3.27) (3.46)
Free cash flow 4.66 4.17 4.78 0.29 4.31 5.06 (2.93) 0.83 (1.22) 0.35
Book value 75.51 90.75 86.72 77.15 78.70 91.15 63.81 62.77 46.39 26.14
Shares, m 41 41 40 45 46 51 54 54 55 57
Valuation, ×
Valuation, × P/E 20.35 18.73 10.25 0.00 70.77 54.94 0.00 0.00 0.00 0.00
P/S 0.82 1.45 0.66 0.85 2.68 2.84 1.88 1.77 1.15 0.68
P/B 0.84 0.76 0.41 0.81 0.84 0.87 0.85 0.88 0.95 1.02
EV/Sales 1.16 1.79 1.17 1.51 4.58 3.82 2.03 2.03 1.76 1.24
EV/FCF 19.30 20.23 13.38 377.79 26.10 21.06 (20.03) 76.59 (55.16) 139.62
Cash, $m
Cash, $m Operating cash flow 247 219 226 131 302 356 (56) 135 114 217
Capex (56) (48) (35) (118) (105) (97) (103) (90) (181) (197)
Free cash flow 191 171 192 13 197 259 (159) 45 (67) 20
Balance, $m
Balance, $m Working capital 679 972 759 547 550 1,280 230 527 617 609
Total debt 1,292 1,061 1,197 2,312 2,231 2,086 259 466 1,330 1,297
Net debt 1,083 649 1,120 2,202 2,134 1,406 235 430 1,281 1,260
Shareholders’ equity 3,093 3,727 3,477 3,490 3,588 4,661 3,450 3,421 2,564 1,492
Returns, %
Returns, % ROA 1.96 2.32 2.10 (7.54) 0.58 0.90 (0.21) (0.76) (17.89) (27.69)
ROIC 3.54 1.94 2.06 2.24 (0.72) (0.65) (1.21) (1.07) (12.61) (25.53)
ROE 4.04 4.43 3.89 (15.15) 1.20 1.74 (0.33) (0.97) (27.59) (58.40)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Enovis Corporation vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
BVS Bioventus Inc. $1.2B 16.4× 21.4× +3.76% (above 0%: growing) +345.45% (above 0%: growing) −25.11% (below 0%: shrinking) 68.97% 12.48% Compare
TNDM Tandem Diabetes Care, Inc. $1.2B — (loss-making) — (loss-making) +5.77% (above 0%: growing) n/m −146.34% (below 0%: shrinking) 56.87% (5.42%) Compare
IRMD iRadimed Corporation $1.1B 48.5× 48.7× +0.28% (above 0%: growing) −8.89% (below 0%: shrinking) +11.66% (above 0%: growing) 74.07% 31.23% Compare
ENOV Enovis Corporation $1.1B — (loss-making) 195× +3.23% (above 0%: growing) n/m +815.79% (above 0%: growing) 61.64% 2.99%
AORT Artivion, Inc. $1.1B — (loss-making) 142× +11.32% (above 0%: growing) n/m −202.47% (below 0%: shrinking) 64.03% (6.65%) Compare
CBLL CeriBell, Inc. $1.1B — (loss-making) — (loss-making) +32.54% (above 0%: growing) n/m −68.63% (below 0%: shrinking) 92.32% (71.11%) Compare
IART Integra LifeSciences Holdings Corporation $1.1B — (loss-making) 26.1× +0.76% (above 0%: growing) n/m +193.48% (above 0%: growing) 52.47% 4.61% Compare
LMRI Lumexa Imaging Holdings, Inc. $1.0B — (loss-making) 14.2× +7.82% (above 0%: growing) n/m +257.54% (above 0%: growing) 14.72% 8.72% Compare
PRCT PROCEPT BioRobotics Corporation $1.0B — (loss-making) — (loss-making) +19.34% (above 0%: growing) n/m −24.43% (below 0%: shrinking) 66.01% (28.98%) Compare
Median of peers $1.1B — 26.1× +6.80% — −24.77% 65.02% (0.40%)

All 149 Medical Devices stocks →

Enovis Corporation (ENOV) key facts

  • Strength: Enovis Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 6.66% from fiscal 2024.
  • Enovis Corporation (ENOV) is a Medical Devices company in the Healthcare sector, listed on the New York Stock Exchange.
  • As of October 16, 2026, ENOV traded at $19.59, a market capitalization of $1.1 billion.
  • Return on equity was −58.4% and debt-to-equity 0.87.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −0.34 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Enovis Corporation (ENOV) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/ENOV · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com